GW Pharmaceuticals (Nasdaq: GWPH) reported positive results from a Phase 3 study of its cannabis based drug Epidiolex to treat Dravet syndrome, a severe form of epilepsy. Shares of the biopharmaceutical more than doubled by leaping $46.25 to close at $84.71.
